fluoxetine hydrochloride (Tocris Bioscience, Oakville ON, Canada), escitalopram oxalate (Tocris Biosceicne) and ketamine (Narketan 10, Vetoquinol, Lavaltrie, QC, Canada) were diluted in 0.9% NaCl solution and administered IP as follows: acute fluoxetine, 1 dose of 3 mg kg‒1 (behavioral testing/tissue collection occurred 0.5 h after injection); chronic fluoxetine, 14 doses (daily) of 10 mg kg‒1 (tissue collection occurred 0.5 h after last injection); repeated citalopram 3 doses of 10 mg kg‒1 (24, 5 and 0.5 h before tissue collection); ketamine (10 mg kg‒1) 1 or 24 h before behavioral testing/tissue collection or mPFC whole-cell recordings.
Aguilar-Valles A., Haji N., De Gregorio D., Matta-Camacho E., Eslamizade M.J., Popic J., Sharma V., Cao R., Rummel C., Tanti A., Wiebe S., Nuñez N., Comai S., Nadon R., Luheshi G., Mechawar N., Turecki G., Lacaille J.C., Gobbi G, & Sonenberg N. (2018). Translational control of depression-like behavior via phosphorylation of eukaryotic translation initiation factor 4E. Nature Communications, 9, 2459.
+ Open protocol